These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28144693)

  • 41. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
    Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
    Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia.
    Maluta S; Dall'oglio S; Nadalini L
    Int J Hyperthermia; 2010; 26(8):765-74. PubMed ID: 21043571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patients aged more than 70 had higher risk of locally advanced prostate cancers and biochemical recurrence in Korea.
    Kim JK; Cho SY; Jeong CW; Lee SB; Ku JH; Hong SK; Byun SS; Kwak C; Him HH; Lee SE; Jeong H
    BJU Int; 2012 Aug; 110(4):505-9. PubMed ID: 22314007
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
    Chakravarti A; DeSilvio M; Zhang M; Grignon D; Rosenthal S; Asbell SO; Hanks G; Sandler HM; Khor LY; Pollack A; Shipley W;
    J Clin Oncol; 2007 Jul; 25(21):3082-9. PubMed ID: 17634487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Radiation-based approaches to the management of T3 prostate cancer.
    Zietman AL; Westgeest JC; Shipley WU
    Semin Urol Oncol; 1997 Nov; 15(4):230-8. PubMed ID: 9421450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term results of adjuvant hormonal therapy plus radiotherapy following radical prostatectomy for patients with pT3N0 or pT3N1 prostate cancer.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2004 Jun; 11(6):397-401. PubMed ID: 15157209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
    Hussain A; Wu Y; Mirmiran A; DiBiase S; Goloubeva O; Bridges B; Mannuel H; Engstrom C; Dawson N; Amin P; Kwok Y
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):167-74. PubMed ID: 21036487
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Comparison of four treatment options for low-risk prostate cancer: Preference-based randomized study for the evaluation of four treatment modalities in prostate cancer with low or "early intermediate" risk (PREFERE) - trial AP 65/11 of the AUO].
    Rexer H; Bussar-Maatz R
    Urologe A; 2015 May; 54(5):723-5. PubMed ID: 25802104
    [No Abstract]   [Full Text] [Related]  

  • 49. Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate.
    Lawton CA
    Semin Radiat Oncol; 2003 Apr; 13(2):141-51. PubMed ID: 12728443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
    Schick U; Jorcano S; Nouet P; Rouzaud M; Vees H; Zilli T; Ratib O; Weber DC; Miralbell R
    Acta Oncol; 2013 Nov; 52(8):1622-8. PubMed ID: 23544357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Locally advanced prostate cancer: current controversies and optimisation opportunities.
    Sridharan S; Dal Pra A; Catton C; Bristow RG; Warde P
    Clin Oncol (R Coll Radiol); 2013 Aug; 25(8):499-505. PubMed ID: 23680106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Metastatic, hormone-naive prostate cancer interventional study : Multicenter, prospective, randomized study to evaluate the effect of standard drug therapy with or without radical prostatectomy in patients with limited bone metastasized prostate cancer (G-RAMPP - the AUO AP 75/13 study)].
    Rexer H
    Urologe A; 2015 Nov; 54(11):1613-6. PubMed ID: 26573673
    [No Abstract]   [Full Text] [Related]  

  • 53. [Focal dose escalation in the treatment of prostate cancer : Long-term results of HDR brachytherapy].
    Cordes J; Broschk J; Sommerauer M; Jocham D; Merseburger AS; Melchert C; Kovács G
    Urologe A; 2017 Feb; 56(2):157-166. PubMed ID: 27376359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
    Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
    Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
    Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
    Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
    Mayer FJ; Crawford ED
    Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Salvage cryotherapy for local recurrence after radiotherapy for prostate cancer.
    Kvorning Ternov K; Krag Jakobsen A; Bratt O; Ahlgren G
    Scand J Urol; 2015 Apr; 49(2):115-9. PubMed ID: 25428754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolving role of surgery, radiation, hormone therapy, and chemotherapy in high-risk locally advanced prostate cancer.
    Mannuel HD; Hussain A
    Clin Genitourin Cancer; 2006 Jun; 5(1):43-9. PubMed ID: 16859578
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Radiotherapy versus radiotherapy plus hormone therapy in the case of isolated PSA increase after radical prostatectomy. A prospective multicenter Phase III study of the AUO (AP 26/99) and the ARO (00/01)].
    Schwarz R; Rexer H
    Urologe A; 2004 Feb; 43(2):194-6. PubMed ID: 14991123
    [No Abstract]   [Full Text] [Related]  

  • 60. [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
    Rexer H
    Urologe A; 2011 Apr; 50(4):489-92. PubMed ID: 21472622
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.